News for Eisai Co., Ltd. (ESALY)

TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (”œAllarity” or the ”œCompany”) ( ALLR), a Phase 2 clinical-stage pharmaceuti

TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (”œAllarity” or the ”œCompany”) ( ALLR), a Phase 2 clinical-stage pharmaceutical co

In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rat

TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (”œAllarity” or the ”œCompany”) ( ALLR), a Phase 2 clinical-stage pharmaceuti

**media[652303]**

SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (”œGyre”) ( GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to ad

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid tariffs and restructuring in pharma.

TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (”œAllarity” or the ”œCompany”) ( ALLR), a Phase 2 clinical-stage pharmaceutical c

TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (”œAllarity” or the ”œCompany”) ( ALLR), a Phase 2 clinical-stage pharmaceutic

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM

Eisai Co., Ltd. (OTCPK:ESALF) Q4 2025 Earnings Conference Call May 15, 2025 2:30 AM ETCompany ParticipantsHaruo Naito - Representative Corporate Officer...

The following slide deck was published by Eisai Co., Ltd.

Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD”‘1/L1 therapySEE

TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (”œAllarity” or the ”œCompany”) ( ALLR), a Phase 2 clinical-stage pharmaceutic

**media[605555]**

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia

**media[596172,596173]**

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform

**media[578202]**